Kevin C. Conlon, M.D.

Kevin C. Conlon, M.D.
Associate Research Physician
Lymphoid Malignancies Branch

Dr. Conlon received his M.D. from Rush Medical College. After completing his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center and serving as chief medical resident, Dr. Conlon completed a fellowship in medical oncology at NCI, where he remained to continue his translational research in the Biological Response Modifiers Program. He left NCI to become a medical officer at the Center for Biologics Evaluation and Research at the FDA, and later a clinical director at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon subsequently returned to Rush University Section of Medical Oncology to continue his clinical and translational immunotherapy efforts. He then returned to NCI first joining the Investigational Drug Branch of CTEP and, most recently, the Metabolism Branch of CCR where the focus of his research is IL-15 and other immunotherapeutics.

Areas of Expertise

1) immunotherapy, 2) IL-15

Contact Info

Kevin C. Conlon, M.D.
Center for Cancer Research
National Cancer Institute
Building 10 - Magnuson Clinical Center, Room 3B38
Bethesda, MD 20892
Ph: 240-760-6087
Fax: 301-480-4442
conlonkc@mail.nih.gov

Selected Publications

  1. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.
    Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM.
    J. Immunother.. 35: 629-40, 2012. [ Journal Article ]
  2. Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.
    Simone CB, Morris JC, Stewart DM, Urquhart NE, Janik JE, Kreitman RJ, Lita E, Conlon K, Wharfe G, Waldmann TA, Kaushal A.
    Blood. 120: 1816-9, 2012. [ Journal Article ]
  3. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
    Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA.
    Blood. 121: 2029-37, 2013. [ Journal Article ]
  4. Phase 1 trial of IL-15 trans presentation blockade using humanized Mikß1 mAb in patients with T-cell large granular lymphocytic leukemia.
    Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC.
    Blood. 121: 476-84, 2013. [ Journal Article ]

Dr. Conlon received his M.D. from Rush Medical College. After completing his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center and serving as chief medical resident, Dr. Conlon completed a fellowship in medical oncology at NCI, where he remained to continue his translational research in the Biological Response Modifiers Program. He left NCI to become a medical officer at the Center for Biologics Evaluation and Research at the FDA, and later a clinical director at the Genetics Institute in Cambridge, Massachusetts. Dr. Conlon subsequently returned to Rush University Section of Medical Oncology to continue his clinical and translational immunotherapy efforts. He then returned to NCI first joining the Investigational Drug Branch of CTEP and, most recently, the Metabolism Branch of CCR where the focus of his research is IL-15 and other immunotherapeutics.

Name Position
Jennifer Hsu R.N. Research Nurse
Nancy Beltran Patient Care Coordinator (Contr.)
Bonita Bryant Medical Technologist
Erin Corcoran Data Manager (Contr.)
Cathryn Lee Clinical Collaborator
Arlethia Spencer Secretary
Search all
CCR clinical trials